Journal: Clinics

Article Title: Mesenchymal stem cells in lung diseases and their potential use in COVID-19 ARDS: A systematized review

doi: 10.1016/j.clinsp.2023.100237

Figure Lengend Snippet: Narrative reviews on the administration of ASCs in chronic or acute lung diseases.

Article Snippet: Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19 (2020) , • Phase II randomized, double-blind, placebo-control study conducted in multiple clinic facilities , • 200 participants (> 18 years; male or female; have banked AdMSCs in Celltex; written informed consent; highly susceptible to SARS-CoV-2 infections, no terminal stages; no previous COVID-19 history, SARS-CoV-2 RT-PCR or equivalent tests negative; SARS-CoV-2 IgM and IgG negative) , • Three doses of 200 million autologous adipose derived mesenchymal stem cells via intravenously infusion every three days , • Three doses of placebo via intravenously infusion every three days. , • Primary outcomes: Assessment of the total number of AEs/SAEs related and non-related with the medication [Time Frame: 6 months]; Proportion of AEs/SAEs related and non-related with the ASCs infusions as compared to the control group [Time Frame: 6 months]; COVID-19 incidence rates [Time Frame: 6 months] , Not yet recruiting.

Techniques: Histopathology, Immunohistochemistry, Clinical Proteomics, Derivative Assay, Genetically Modified, Activity Assay, Generated

Journal: Clinics

Article Title: Mesenchymal stem cells in lung diseases and their potential use in COVID-19 ARDS: A systematized review

doi: 10.1016/j.clinsp.2023.100237

Figure Lengend Snippet: Published clinical trials on the administration of ASCs in chronic or acute lung diseases.

Article Snippet: Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19 (2020) , • Phase II randomized, double-blind, placebo-control study conducted in multiple clinic facilities , • 200 participants (> 18 years; male or female; have banked AdMSCs in Celltex; written informed consent; highly susceptible to SARS-CoV-2 infections, no terminal stages; no previous COVID-19 history, SARS-CoV-2 RT-PCR or equivalent tests negative; SARS-CoV-2 IgM and IgG negative) , • Three doses of 200 million autologous adipose derived mesenchymal stem cells via intravenously infusion every three days , • Three doses of placebo via intravenously infusion every three days. , • Primary outcomes: Assessment of the total number of AEs/SAEs related and non-related with the medication [Time Frame: 6 months]; Proportion of AEs/SAEs related and non-related with the ASCs infusions as compared to the control group [Time Frame: 6 months]; COVID-19 incidence rates [Time Frame: 6 months] , Not yet recruiting.

Techniques: Clinical Proteomics, Control, Transplantation Assay, Infection

Journal: Clinics

Article Title: Mesenchymal stem cells in lung diseases and their potential use in COVID-19 ARDS: A systematized review

doi: 10.1016/j.clinsp.2023.100237

Figure Lengend Snippet: Unpublished clinical trials on the administration of ASCs in chronic or acute lung diseases.

Article Snippet: Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19 (2020) , • Phase II randomized, double-blind, placebo-control study conducted in multiple clinic facilities , • 200 participants (> 18 years; male or female; have banked AdMSCs in Celltex; written informed consent; highly susceptible to SARS-CoV-2 infections, no terminal stages; no previous COVID-19 history, SARS-CoV-2 RT-PCR or equivalent tests negative; SARS-CoV-2 IgM and IgG negative) , • Three doses of 200 million autologous adipose derived mesenchymal stem cells via intravenously infusion every three days , • Three doses of placebo via intravenously infusion every three days. , • Primary outcomes: Assessment of the total number of AEs/SAEs related and non-related with the medication [Time Frame: 6 months]; Proportion of AEs/SAEs related and non-related with the ASCs infusions as compared to the control group [Time Frame: 6 months]; COVID-19 incidence rates [Time Frame: 6 months] , Not yet recruiting.

Techniques: Clinical Proteomics, Derivative Assay, Biomarker Discovery, Isolation, Saline, Transplantation Assay, Concentration Assay, Functional Assay, Control, Infection, Reverse Transcription Polymerase Chain Reaction, Activity Assay, Comparison, Injection, Computed Tomography, Sterility, Coagulation

Journal: ACS nano

Article Title: Inducing Stem Cell Myogenesis Using NanoScript

doi: 10.1021/acsnano.5b00709

Figure Lengend Snippet: NanoScript-MRF initiates transcription and activation of myogenic genes. (a) After 7 days post-treatment with NanoScript-MRF, qPCR analysis reveals overexpression of targeted MRFs as well as significant expression of the late-stage myogenic gene MYH1by NanoScript-MRF (red) as compared to the untreated control (gray). (b) Multipotent genes of ADMSCs were down-regulated as compared to untreated control cells, thus indicating that stem properties of ADMSCs are repressed when myogenic genes are overexpressed. Error bars are from three independent trials, and mRNA expression is represented as a fold change compared to the control.

Article Snippet: ADMSC Culture and Myogenic Differentiation The human ADMSCs (American CryoStem) and the 0.5% fetal bovine serum growth media were provided by American CryoStem.

Techniques: Activation Assay, Over Expression, Expressing, Control

Journal: Obesity Reviews

Article Title: Using adipose‐derived mesenchymal stem cells to fight the metabolic complications of obesity: Where do we stand?

doi: 10.1111/obr.13413

Figure Lengend Snippet: The most relevant preclinical studies pertaining to the therapeutic exploitation of adipose‐derived mesenchymal stem cells (ADMSCs) in the treatment of obesity and its metabolic complications in various animal models

Article Snippet: Rat ADMSCs , 3 × 10 6 ADMSCs were injected through the tail vein once a week for 24 weeks. , Male Sprague–Dawley (SD) rats A long‐term T2DM complication rat model. , 8 weeks , Normal chow diet (NCD) or a high‐fat diet (HFD; 60% fat) for 8 weeks , 24 weeks , Decreased , The level of circulating TGs, TC and LDL‐C was markedly reduced. , Persistent and gradual decrease in blood glucose level. Glucose clearance was improved in the ADMSCs‐treated group. , A marked enhancement in insulin sensitivity after the ADMSCs multiple infusions. , Pancreatic islet function was markedly restored. The ratio of insulin‐positive cells per islet was increased. , Reduction in TNF‐α, IL1β, TGF‐β and increase in anti‐inflammatory molecule IL‐10. , ADMSCs significantly decreased col1 transcripts and TIMP‐1, MMP‐2, 8, and 9. , Yu et al. .

Techniques: Animal Model, Injection, Clinical Proteomics, Suspension, Concentration Assay, Preserving, Expressing, Transplantation Assay